Home > News > Veristat advances game changing pain and inflammation therapy

1 min read

Veristat Advances Game-Changing Pain and Inflammation Therapy

Clinical Trials Project Management Clinical Operations/Monitoring

Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. 

Veristat will conduct the study in a total of 360 patients with osteoarthritis (“OA”) of the knee, across approximately 35 clinical sites in Canada.   Using our proven patient recruitment and site engagement techniques, we will commence enrollment immediately.  

Read the full  press release on the Antibe Therapeutics website.

Veristat’s full-high_science_homepagehero_1439x643service clinical development solutions are ideal for emerging and small to mid-size biopharmaceutical companies.    We deliver uncompromised value and impact to our clients as we guide them from early phase trial planning and design, through to trial execution, regulatory submission support through to post-approval.  

 

Explore Key Related Services:

2 min read

Connect with Veristat at Bio International Convention 2026

Jun 15, 2026  Veristat Events

June 22-25, 2026 – San Diego, CA

🌎 Bringing the Global Biopharma Community Together

We’re delighted to be attending...

2 min read

Connect with Veristat at DIA 2026

Jun 5, 2026  Veristat Events

June 14-18, 2026 – Philadelphia, PA

Veristat is excited to join industry leaders and innovators at the DIA 2026 Global...